Logo image of HOTH

HOTH THERAPEUTICS INC (HOTH) Stock Fundamental Analysis

NASDAQ:HOTH - Nasdaq - US44148G2049 - Common Stock

1.36  -0.06 (-4.23%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to HOTH. HOTH was compared to 195 industry peers in the Pharmaceuticals industry. While HOTH has a great health rating, there are worries on its profitability. HOTH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HOTH has reported negative net income.
In the past year HOTH has reported a negative cash flow from operations.
In the past 5 years HOTH always reported negative net income.
In the past 5 years HOTH always reported negative operating cash flow.
HOTH Yearly Net Income VS EBIT VS OCF VS FCFHOTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -5M -10M

1.2 Ratios

The Return On Assets of HOTH (-90.37%) is worse than 76.34% of its industry peers.
HOTH has a Return On Equity (-100.18%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -90.37%
ROE -100.18%
ROIC N/A
ROA(3y)-126.94%
ROA(5y)-157.87%
ROE(3y)-151.97%
ROE(5y)-186.32%
ROIC(3y)N/A
ROIC(5y)N/A
HOTH Yearly ROA, ROE, ROICHOTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HOTH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HOTH Yearly Profit, Operating, Gross MarginsHOTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, HOTH has more shares outstanding
The number of shares outstanding for HOTH has been increased compared to 5 years ago.
There is no outstanding debt for HOTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HOTH Yearly Shares OutstandingHOTH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
HOTH Yearly Total Debt VS Total AssetsHOTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

HOTH has an Altman-Z score of -4.59. This is a bad value and indicates that HOTH is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.59, HOTH is doing worse than 63.98% of the companies in the same industry.
HOTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.59
ROIC/WACCN/A
WACCN/A
HOTH Yearly LT Debt VS Equity VS FCFHOTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 10.16 indicates that HOTH has no problem at all paying its short term obligations.
The Current ratio of HOTH (10.16) is better than 82.80% of its industry peers.
A Quick Ratio of 10.16 indicates that HOTH has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.16, HOTH belongs to the top of the industry, outperforming 82.80% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.16
Quick Ratio 10.16
HOTH Yearly Current Assets VS Current LiabilitesHOTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

HOTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.91%, which is quite impressive.
EPS 1Y (TTM)72.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.12% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y45.34%
EPS Next 2Y30.17%
EPS Next 3Y20.12%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HOTH Yearly Revenue VS EstimatesHOTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
HOTH Yearly EPS VS EstimatesHOTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HOTH. In the last year negative earnings were reported.
Also next year HOTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HOTH Price Earnings VS Forward Price EarningsHOTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HOTH Per share dataHOTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

HOTH's earnings are expected to grow with 20.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.17%
EPS Next 3Y20.12%

More info and screens

0

5. Dividend

5.1 Amount

HOTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HOTH THERAPEUTICS INC

NASDAQ:HOTH (1/22/2025, 4:30:01 PM)

1.36

-0.06 (-4.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners5.05%
Inst Owner Change0%
Ins Owners0.93%
Ins Owner Change0.53%
Market Cap9.38M
Analysts82.5
Price Target4.59 (237.5%)
Short Float %9.26%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.95%
Min EPS beat(2)10.61%
Max EPS beat(2)45.28%
EPS beat(4)3
Avg EPS beat(4)22.37%
Min EPS beat(4)-4.88%
Max EPS beat(4)45.28%
EPS beat(8)6
Avg EPS beat(8)17.25%
EPS beat(12)9
Avg EPS beat(12)14.53%
EPS beat(16)11
Avg EPS beat(16)7.34%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)29.07%
EPS NY rev (1m)0%
EPS NY rev (3m)1.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.25
P/tB 1.25
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS1.09
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -90.37%
ROE -100.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-126.94%
ROA(5y)-157.87%
ROE(3y)-151.97%
ROE(5y)-186.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.16
Quick Ratio 10.16
Altman-Z -4.59
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.33%
EPS Next Y45.34%
EPS Next 2Y30.17%
EPS Next 3Y20.12%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.72%
OCF growth 3YN/A
OCF growth 5YN/A